<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20220">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843659</url>
  </required_header>
  <id_info>
    <org_study_id>IM128-035</org_study_id>
    <secondary_id>2016-000101-37</secondary_id>
    <nct_id>NCT02843659</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome</brief_title>
  <official_title>A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of treatment with either
      lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren's
      syndrome as measured by the change from baseline in ESSDAI at Week 12 between active
      treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2016</start_date>
  <completion_date type="Anticipated">September 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in EULAR SS Disease Activity Index (ESSDAI) score at Week 12</measure>
    <time_frame>From Day 1 and Week 12</time_frame>
    <description>Changes will be compared between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EULAR SS Patient-Related Index (ESSPRI) score at Week 12</measure>
    <time_frame>From Day 1 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 3 points of improvement from baseline in ESSDAI at Week 12</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 1 point of improvement from baseline in ESSPRI at Week 12</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with both ≥ 3 points improvement in ESSDAI and ≥ 1 point improvement in ESSPRI from baseline at Week 12</measure>
    <time_frame>Day 1 to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSDAI scores at Week 4 and Week 8</measure>
    <time_frame>Up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI scores at Week 4 and Week 8</measure>
    <time_frame>Up to 8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI individual component dryness score at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI individual component fatigue score at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI individual component pain score at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in unstimulated salivary flow rate at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stimulated salivary flow rate at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ocular surface staining test at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Schirmer's test at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the tear break-up time test at Weeks 4, 8, and 12</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all Adverse Events (AEs), Serious Adverse Events (SAEs), and any pre-established Events of Special Interest for lulizumab</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in general laboratory tests for lulizumab</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant ECG abnormalities for lulizumab</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in vital signs for lulizumab</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all Adverse Events (AEs), Serious Adverse Events (SAEs), and any pre-established Events of Special Interest for BMS-986142</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in general laboratory tests for BMS-986142</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant ECG abnormalities for BMS-986142</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant abnormalities in vital signs for BMS-986142</measure>
    <time_frame>Up to 18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) for mouth dryness</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) for eye dryness</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS) for vaginal dryness</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Assessment of Disease activity</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of Disease activity</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 acute (SF-36 acute)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Participation and Activity Impairment Questionnaire (WPAI)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System Fatigue Short Form (PROMIS Fatigue Short Form)</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentrations of lulizumab and BMS-986142 in pSS subjects</measure>
    <time_frame>Day 1 to Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>BMS-931699</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous weekly injection + daily oral placebo tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986142</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral tablets + subcutaneous placebo (weekly) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly subcutaneous placebo injection +daily oral placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-931699</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-931699</arm_group_label>
    <other_name>lulizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986142</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-986142</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>BMS-931699</arm_group_label>
    <arm_group_label>BMS-986142</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects diagnosed or classified as having moderate to severe primary Sjögren's
             Syndrome based on the 2016 ACR-EULAR Sjögren's Syndrome Classification Criteria for
             at least 16 weeks prior to screening

          -  ESSDAI ≥ 5 including disease activity (any score &gt; 0) in at least one of the
             following domains: Glandular, Articular, Hematological, Biological, Lymphadenopathy

          -  Positive anti-SS-A/Ro and/or anti-SS-B/La autoantibody

          -  Unstimulated whole saliva secretion &gt; 0.01 ml/min

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior
             to the start of study drug and must not be pregnant or breastfeeding. Male and female
             subjects must be willing to adhere to protocol-mandated highly effective
             contraception for the duration of the study and for the protocol-specified follow up
             period. Hormone-based contraceptive methods are not permitted

        Exclusion Criteria:

          -  Secondary Sjögren's syndrome or the presence of any other systemic autoimmune disease
             (eg, RA, SLE, multiple sclerosis, vasculitis)

          -  Very severe primary Sjögren's syndrome or severe complications of primary Sjögren's
             syndrome at the time of the screening visit

          -  Active systemic or latent bacterial (including tuberculosis), viral or fungal
             infection, evidence of current or chronic Hepatitis B or C infection, or HIV
             infection

          -  Any significant concurrent medical condition at the time of screening or baseline
             visit

          -  Use of methotrexate, cyclophosphamide, cyclosporine, tacrolimus, azathioprine,
             mycophenolate mofetil (MMF) or leflunomide within 12 weeks of screening visit

          -  Previous treatment with biologics therapies either marketed or in development within
             6 months prior to screening visit

          -  Treatment started or an unstable dose of hydroxychloroquine within 8 weeks of
             screening visit

          -  Oral corticosteroids &gt; 10 mg/day within 14 days of dosing (Day 1), corticosteroid
             therapy ≥ 1 mg/kg during the 4 weeks preceding enrollment, or intravenous,
             intramuscular or intra-articular corticosteroids within 4 weeks of screening visit

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0012, Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>PaloAlto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0054</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0020, Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Birbara, Site 0016</last_name>
      <phone>508-755-0201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0038</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0052</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0048</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0031</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pmg Research Of Wilmington Llc</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald George, Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, Llc</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isam Diab, Site 0046</last_name>
      <phone>440-826-0742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Kivitz, Site 0042</last_name>
      <phone>814-693-0300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0044</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0047, Site 0047</last_name>
      <phone>731-633-0119</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Pickrell, Site 0029</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0033</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0032</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago De Chile</city>
        <state>Metropolitana</state>
        <zip>7501126</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0034</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Puerto Varas</city>
        <zip>5550170</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0041</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0062</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Fededral</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0036</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cercado De Lima</city>
        <state>Lima</state>
        <zip>1</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 33</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0043, Site 0043</last_name>
      <phone>7877268396</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0060</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0061</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parktown</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0035</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stellenbosch</city>
        <state>Western Cape</state>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>July 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
